GoodRx Earns 'Modest Buy' Consensus Rating from Analysts

Summary

GoodRx Holdings, Inc. (NASDAQ: GDRX) received a ‘moderate buy’ consensus rating from eleven analysts, with an average 12-month target price of $6.55. Of these, five analysts rated it as hold, five as buy, and one as strong buy. Recent price target adjustments include UBS lowering its target to $5.25 and Wells Fargo lowering to $7.00. The stock opened at $4.37 with a market cap of $1.56 billion. The company reported quarterly earnings per share of $0.09, exceeding expectations, and revenue of $202.97 million, up 2.6% year-over-year.Market Beat

Impact Analysis

This event is classified at the company level as it specifically pertains to GoodRx’s stock ratings and financial performance. The analyst ratings and price target adjustments directly impact investor sentiment and potential stock price movements. GoodRx’s better-than-expected earnings and revenue growth suggest positive business performance, providing potential investment opportunities. However, the reduction in price targets by UBS and Wells Fargo highlights caution among analysts, reflecting potential risks or market uncertainties. Investors might consider the mixed ratings and recent earnings as indicators for gauging GoodRx’s short-term stock performance and align this with their investment strategy.Market Beat